Tags

Type your tag names separated by a space and hit enter

Prevalence of diagnosed opioid abuse and its economic burden in the veterans health administration.
Pain Pract. 2014 Jun; 14(5):437-45.PP

Abstract

OBJECTIVE

Evaluate prevalence and risk-adjusted healthcare costs of diagnosed opioid abuse in the national Veterans Health Administration (VHA). Costs were compared between patients with and without diagnosed opioid abuse.

DESIGN

Medical and pharmacy claims analysis of VHA data (10/01/2006 to 09/30/2010) were retrospectively analyzed. Prevalence was calculated as the percent of patients with diagnosed opioid abuse for the entire VHA membership and those with noncancer pain diagnoses, compared between patients prescribed opioids prior to abuse diagnosis and those not prescribed opioids through the VHA system. Healthcare utilization and costs were estimated using matching techniques and generalized linear models to control for clinical and demographic differences between patients with and without diagnosed opioid abuse. Separate comparisons were made (with diagnosed abuse vs. without) for each cohort: patients with/without opioid prescriptions.

RESULTS

Five-year diagnosed opioid abuse was 1.11%. Among patients prescribed opioids, 5-year abuse prevalence was 3.04%. Pain patients prescribed opioids had the highest abuse rate at 3.26%. Adjusted annual healthcare costs for diagnosed opioid abuse patients were higher than for those without diagnosed abuse, (prescribed opioids overall healthcare costs: $28,882, with diagnosed abuse vs. $13,605 for those without; not prescribed opioids: $25,197 vs. $6350, P-value< 0.0001; opioid-specific healthcare costs for patients prescribed opioids: $8956 vs. $218; patients not prescribed opioids: $8733 vs. $20).

CONCLUSIONS

Diagnosed opioid abuse prevalence is almost 7-fold higher in the veteran's administration population than in commercial health plans and translates to a significant economic burden. Appropriate interventions should be considered to prevent and reduce opioid abuse.

Authors+Show Affiliations

STATinMED Research and The University of Michigan, Ann Arbor, Michigan, U.S.A.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23809020

Citation

Baser, Onur, et al. "Prevalence of Diagnosed Opioid Abuse and Its Economic Burden in the Veterans Health Administration." Pain Practice : the Official Journal of World Institute of Pain, vol. 14, no. 5, 2014, pp. 437-45.
Baser O, Xie L, Mardekian J, et al. Prevalence of diagnosed opioid abuse and its economic burden in the veterans health administration. Pain Pract. 2014;14(5):437-45.
Baser, O., Xie, L., Mardekian, J., Schaaf, D., Wang, L., & Joshi, A. V. (2014). Prevalence of diagnosed opioid abuse and its economic burden in the veterans health administration. Pain Practice : the Official Journal of World Institute of Pain, 14(5), 437-45. https://doi.org/10.1111/papr.12097
Baser O, et al. Prevalence of Diagnosed Opioid Abuse and Its Economic Burden in the Veterans Health Administration. Pain Pract. 2014;14(5):437-45. PubMed PMID: 23809020.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevalence of diagnosed opioid abuse and its economic burden in the veterans health administration. AU - Baser,Onur, AU - Xie,Lin, AU - Mardekian,Jack, AU - Schaaf,David, AU - Wang,Li, AU - Joshi,Ashish V, Y1 - 2013/06/30/ PY - 2013/01/31/received PY - 2013/05/06/accepted PY - 2013/7/2/entrez PY - 2013/7/3/pubmed PY - 2015/1/27/medline KW - economic burden KW - healthcare costs KW - opioid abuse KW - opioid dependence KW - veterans SP - 437 EP - 45 JF - Pain practice : the official journal of World Institute of Pain JO - Pain Pract VL - 14 IS - 5 N2 - OBJECTIVE: Evaluate prevalence and risk-adjusted healthcare costs of diagnosed opioid abuse in the national Veterans Health Administration (VHA). Costs were compared between patients with and without diagnosed opioid abuse. DESIGN: Medical and pharmacy claims analysis of VHA data (10/01/2006 to 09/30/2010) were retrospectively analyzed. Prevalence was calculated as the percent of patients with diagnosed opioid abuse for the entire VHA membership and those with noncancer pain diagnoses, compared between patients prescribed opioids prior to abuse diagnosis and those not prescribed opioids through the VHA system. Healthcare utilization and costs were estimated using matching techniques and generalized linear models to control for clinical and demographic differences between patients with and without diagnosed opioid abuse. Separate comparisons were made (with diagnosed abuse vs. without) for each cohort: patients with/without opioid prescriptions. RESULTS: Five-year diagnosed opioid abuse was 1.11%. Among patients prescribed opioids, 5-year abuse prevalence was 3.04%. Pain patients prescribed opioids had the highest abuse rate at 3.26%. Adjusted annual healthcare costs for diagnosed opioid abuse patients were higher than for those without diagnosed abuse, (prescribed opioids overall healthcare costs: $28,882, with diagnosed abuse vs. $13,605 for those without; not prescribed opioids: $25,197 vs. $6350, P-value< 0.0001; opioid-specific healthcare costs for patients prescribed opioids: $8956 vs. $218; patients not prescribed opioids: $8733 vs. $20). CONCLUSIONS: Diagnosed opioid abuse prevalence is almost 7-fold higher in the veteran's administration population than in commercial health plans and translates to a significant economic burden. Appropriate interventions should be considered to prevent and reduce opioid abuse. SN - 1533-2500 UR - https://www.unboundmedicine.com/medline/citation/23809020/Prevalence_of_diagnosed_opioid_abuse_and_its_economic_burden_in_the_veterans_health_administration_ L2 - https://doi.org/10.1111/papr.12097 DB - PRIME DP - Unbound Medicine ER -